Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Completed · Phase 1

Conditions studied: Urinary Bladder Neoplasm

In brief

The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.

Key facts

Study ID

NCT02311101

Run by

The University of Texas Health Science Center at San Antonio

People needed

18

Starts

2012-03-01

Expected to finish

2015-04-01

Last updated by the study team

2015-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed or recurrent multi-focal Ta, large Ta, high-grade Ta, CIS, or T1 bladder cancer
• In urologist's opinion a good candidate for BCG induction therapy
• Be able to give informed consent
• Be age 18 or older.

You may not qualify if…

• Inadequate marrow function (defined as granulocytes less than 1,500 cells/mm3 and platelets less than 150,000 cells/mm3)
• Immunosuppressed state (e.g. HIV, use of chronic steroids)

Where it is running

• The University of Texas Health Science Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.